FDA Transparency Initiative: GSK's Tailored Comments Seek To Shape Plan

FDA's transparency initiative has drawn sharp criticism from drug industry organizations fearful that trade secrets will be divulged, but GlaxoSmithKline is taking a different tack in suggesting modifications rather than condemning them outright